Predictors of 30-Day Mortality Among Critically Ill Patients
with Candidemia Identified by T2Candida Panel
Caniff KE et al., Anti-infective Research Laboratory/Wayne State University
Poster on retrospective, multi-center study evaluating predictors of 30-day mortality in patients with known T2Candida
positive results including the following conclusions:
|
|
|
Empiric antifungal administration and ID consultation are modifiable risk factors that were independently
associated with reduced odds of 30-day mortality in patients with candidemia identified by T2Candida Panel, highlighting their importance in clinical management |
|
|
|
Real-world use of theT2Candida Panel allowed for rapid identification of candidemia and prompt initiation
of definitive therapy |
Rapid Detection of Antibiotic Resistance Genes Direct from Whole Blood Samples by T2 Magnetic
Resonance (T2MR®)
Wang J et al., T2Biosystems
T2 Biosystems authored poster on analytical studies evaluating the limit of detection, analytical reactivity/inclusivity, interfering substances, and
analytical specificity/exclusivity of the T2Resistance Panel.
|
|
|
Limit of detection for all 13 genes was <20 CFU/mL (ranging from 3-18
CFU/mL). |
|
|
|
The panel has broad inclusivity of resistance gene variants, no observed interfering substances from those
tested, and no observed cross-reactivity with other species or resistance markers. |
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing
the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, the T2Biothreat Panel, and the T2SARS-CoV-2 Panel and are powered by
the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the Acinetobacter baumannii test, the Candida auris
test, and the T2Lyme Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information,
please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in
this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the detection capabilities of the Companys T2Dx Instrument and sepsis test
panels, the clinical and economic benefits of the Companys technology, and the real world performance and benefits of the Companys sepsis products , as well as statements that include the words expect, may,
should, anticipate, and similar statements of a future or forward-looking nature. These forward-looking statements are based on managements current expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments,